Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 2/20 | 0.59 |
| ▸ | F2 | P00734 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.41 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.38 |
| ▸ | SCN4A | P35499 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14344017 | 1.00 | DPP4 (0.59) | DPP4F2THRBADRA2AADRA2C | |
| SCHEMBL14344178 | 1.00 | DPP4 (0.59) | DPP4F2THRBADRA2AADRA2C | |
| Hydrochloric Acid SCHEMBL7961646 | 0.98 | DPP4 (0.56) | DPP4F2THRBADRA2AADRA2C | |
| SCHEMBL22225738 | 0.79 | DPP4 (0.56) | DPP4F2THRBADRA2AADRA2C | |
| SCHEMBL851654 | 0.76 | DPP4 (1.00) | DPP4F2ADRA2AADRA2CLMNA | |
| SCHEMBL1878642 | 0.76 | DPP4 (1.00) | DPP4F2ADRA2AADRA2CLMNA | |
| SCHEMBL239938 | 0.76 | DPP4 (1.00) | DPP4F2ADRA2AADRA2CLMNA | |
| SCHEMBL2067094 | 0.76 | DPP4 (1.00) | DPP4F2ADRA2AADRA2CLMNA | |
| SCHEMBL644767 | 0.76 | DPP4 (1.00) | DPP4F2ADRA2AADRA2CLMNA | |
| SCHEMBL150159 | 0.76 | DPP4 (1.00) | DPP4F2ADRA2AADRA2CLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114100588-A | Nitrogen-containing functional group ultrahigh cross-linking adsorbent, preparation method thereof and blood perfusion apparatus | 泉州师范学院 | 2022-03-01 | — | — | CN | disclosed |
| CN-110903433-B | Preparation method of sulfonamide based on aminopropyl-3-methylimidazole and synergist molecularly imprinted polymer thereof | 中国农业科学院农业质量标准与检测技术研究所 | 2021-07-13 | — | — | CN | disclosed |
| CN-110903433-A | Preparation method of sulfonamide based on aminopropyl-3-methylimidazole and synergist molecularly imprinted polymer thereof | 中国农业科学院农业质量标准与检测技术研究所 | 2020-03-24 | — | — | CN | disclosed |
| EP-2588455-B1 | 2-QUINOLINYL-ACETIC ACID DERIVATIVES AS HIV ANTIVIRAL COMPOUNDS | GILEAD SCIENCES INC (US) | 2018-04-04 | — | — | EP | disclosed |
| US-9296758-B2 | 2-quinolinyl-acetic acid derivatives as HIV antiviral compounds | GILEAD SCIENCES, INC. (US) | 2016-03-29 | — | — | US | disclosed |
| US-20130210801-A1 | 2-QUINOLINYL-ACETIC ACID DERIVATIVES AS HIV ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2013-08-15 | — | — | US | disclosed |
| CN-103209963-A | 2-quinolinyl-acetic acid derivatives as HIV antiviral compounds | GILEAD SCIENCES INC | 2013-07-17 | — | — | CN | disclosed |
| EP-2588455-A1 | 2 -QUINOLINYL- ACETIC ACID DERIVATIVES AS HIV ANTIVIRAL COMPOUNDS | Gilead Sciences, Inc. (US) | 2013-05-08 | — | — | EP | disclosed |
| WO-2012003498-A1 | 2 -QUINOLINYL- ACETIC ACID DERIVATIVES AS HIV ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2012-01-05 | — | — | WO | disclosed |
| WO-2010031544-A1 | PROCESS FOR PREPARING ALPHA AMINOACETALS IN RECEMIC FORM | CLARIANT SPECIALTY FINE CHEMICALS (FRANCE) (FR) | 2010-03-25 | — | — | WO | disclosed |
| WO-2010031544-A1 | PROCESS FOR PREPARING ALPHA AMINOACETALS IN RECEMIC FORM | CLARIANT SPECIALTY FINE CHEMICALS (FRANCE) (FR) | 2010-03-25 | — | — | WO | disclosed |
| EP-1527041-B1 | PROCESS FOR THE PREPARATION OF PRIMARY AMINES | CLARIANT FRANCE SA (FR) | 2010-03-10 | — | — | EP | disclosed |
| US-7220883-B2 | Process for the preparation of primary amines | CLARIANT (FRANCE) (FR) | 2007-05-22 | — | — | US | disclosed |
| US-20050240059-A1 | Process for the preparation of primary amines | CLARIANT (FRANCE) (FR) | 2005-10-27 | — | — | US | disclosed |
| EP-1001956-B1 | 2,3-BENZODIAZEPINE DERIVATIVES | GYOGYSZERKUTATO INTEZET (HU) | 2003-05-07 | — | — | EP | disclosed |
| US-6482819-B1 | 2,3-benzodiazepine derivatives | GYOGYSZERKUTATO INTEZET KFT. (HU) | 2002-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050240059-A1 | Process for the preparation of primary amines | HRH3, H1-3, H1-0 | DPP4 4876/4885F2 1447/4885THRB 2623/4885 |
| US-20130210801-A1 | 2-QUINOLINYL-ACETIC ACID DERIVATIVES AS HIV ANTIVIRAL COMPOUNDS | NFATC1, ACIN1, ARF1 | DPP4 2009/4885F2 3762/4885THRB 4499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.